Tevogen Bio Holdings Inc. (TVGN)
NASDAQ: TVGN · Real-Time Price · USD
1.290
-0.050 (-3.73%)
At close: May 30, 2025, 4:00 PM
1.320
+0.030 (2.33%)
After-hours: May 30, 2025, 7:45 PM EDT
Tevogen Bio Holdings Employees
Tevogen Bio Holdings had 18 employees as of December 31, 2024.
Employees
18
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,738,041
Market Cap
237.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
TVGN News
- 10 hours ago - Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships - GlobeNewsWire
- 7 days ago - Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow - GlobeNewsWire
- 8 days ago - Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting - GlobeNewsWire
- 18 days ago - Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - GlobeNewsWire
- 4 weeks ago - Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest - GlobeNewsWire
- 4 weeks ago - CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment - GlobeNewsWire
- 4 weeks ago - Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts - GlobeNewsWire
- 4 weeks ago - Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald - GlobeNewsWire